Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is just an LOI. The deal isn't closed yet.
This could be potentially bad news for this stock. I will leave it up to you on this message board to figure out why.
CDIX has 7.5 Billion Authorized shares. That is a bit on the steep side especially given this stock's history.
Its still just an LOI. The deal hasn't been closed yet.
Gee maybe Rick Pitino and John Calipari will buy shares. Maybe Ashley Judd and Mitch McConnell will too. Thanks for the laughs.
He appears to be pumping the stock so note holders can convert. Why would he be seeking all of this publicity before the deal is even finalized. I am starting to get skeptical. What I would like to hear is they have found a friendlier form of financing.
7.5 Billion Authorized Shares as of 8/19/19
This company is notorious for dilution. Just ask people who have owned the stock over the last 3 years. This company is very aggressive with their dilution even by OTC standards
They have had a history of very aggressive dilution. Many here including myself have been burned by them in the past. They need to find friendlier financing.
Other companies have way more debt. Other companies have far less revenues. And yet those stocks trade much higher. It's kind of mind boggling what's going on here.
This stock is not boring
Here we go round 2
Cardiff Lexington Corp (CDIX) And Acela Biomedical, LLC to Merge
10:10 AM ET 8/23/19 | GlobeNewswire
Related Quotes
Cardiff Lexington Corp (CDIX) And Acela Biomedical, LLC to Merge
FT. LAUDERDALE, Fla., Aug. 23, 2019 (GLOBE NEWSWIRE) -- Cardiff Lexington Corporation (OTC:CDIXBB) and Acela BioMedical, LLC in Maysville, Ky announced today that they have signed a Letter of Intent whereby Acela BioMedical would become a subsidiary of Cardiff Lexington. The Management and Board of Directors of Cardiff Lexington Corporation have taken bold, decisive actions in order to enter the ever-growing hemp industry and with Acela BioMedical they have found an ideal partner. Consummation of the partnership is conditional upon successful completion of final stage due diligence and transfer of purchase consideration.
Acela Biomedical, its management and employees are committed to the continued growth and expansion of the Company in Maysville, KY. No operational changes are planned, and current ownership will remain in place under a new structure that empowers significant capital investment to meet the rapidly expanding opportunities and to implement the Company's growth strategies. Andrew Culbertson Acela CEO will also join the Board of Directors of Cardiff Lexington.
The parties have been in confidential discussions and negotiations for several months having reached agreement in principal and are working diligently to finalize their transaction as visualized in their recently executed Letter of Intent. The parties given the strong public interest and much misinformation, rumors, and speculation have decided to publicize their intentions now prior to anticipated future closing.
About Acela BioMedical, LLC
Acela Biomedical is an existing Hemp grower, distributor, processor, extractor, and retailor specializing in CBD Oil Production with over two million plants in the ground in Kentucky. Its processing facility is currently in operation. CBD Hemp Cultivation and CBD Oil Production is a specialized high value agriculture category with more in common horticulture than traditional industrial hemp (fiber and oilseed types). Growing industrial hemp for CBD oil production is approached as a medicinal crop, and grown to suit the requirements of processors and buyers. Acela is building a strong foundation in Kentucky hemp cultivation, production, and processing to deliver consistently higher growth and higher value for our shareholders. Bringing production online at our Kentucky hemp processing plant will represent the Company's latest and most significant milestone toward that objective.
Acela Biomedical will continue as a Kentucky Corporation operating as subsidiary of Cardiff Lexington. "We are excited to join forces with Andrew Culbertson and his exceptional team," stated Alex H. Cunningham, Cardiff Lexington CEO. "Andrew and his team will continue to operate and lead Acela Biomedical growth and expansion; our partnership will accelerate that growth and allow Acela to greatly expand capacity and develop both new products and blaze into new endeavors."
Andrew Culbertson, Founder of Acela Biomedical responded: "We have established deep roots within the Hemp Industry in Kentucky and are committed to supporting our farmers in Kentucky, Ohio, and Tennessee. This new partnership brings Acela the resources and horsepower for us to make a significant positive impact in Kentucky's Hemp Industry and affords us the capability to expand our operations in Ohio, Tennessee, and West Virginia. We too are excited that with our alliance with Cardiff Lexington's to be able to implement many strategies formulated over the past four years."
Cardiff Lexington's business model targets acquisition of middle market private niche companies both mature, and, second stage with high growth potential. The Cardiff Lexington umbrella enables business owners to exit personal equity and to take advantage of the capitalization power of a public company without losing independent management control. Fundamental to the Cardiff Lexington strategy, acquisitions become standalone autonomous subsidiaries gaining advantage of the power of a public company. Owners gain liquidity, diversification, pooled resources, leverage value, and mitigated risk. As a Cardiff Lexington subsidiary these companies gain both the enhanced ability to raise money for operations or expansion while also establishing a longer-term equity exit strategy.
For Investors, Cardiff Lexington seeks to aggressively grow and hold assets that create a diversified lower risk environment that over the long term protects and safely enhances investment through a diversified continually growing niche holding company.
About Cardiff Lexington Corporation: Cardiff Lexington is a public holding company, much like a cooperative, leveraging proven management in private companies that become subsidiaries. Our focus is not industry or geographic-specific, but rather proven management, market, and margin. Cardiff Lexington targets acquisitions of mature, high growth, niche companies. Cardiff Lexington's strategy identifies and empowers select income-producing middle market private businesses and commercial real estate properties. Cardiff Lexington provides these companies both 1) the enhanced ability to raise money for operations or expansion, and 2) an equity exit and liquidity strategy for the owner, heirs, and/or Investors. For investors, Cardiff Lexington provides a diversified lower risk to protect and safely enhance their investment by continually adding assets and holdings. Cardiff Lexington is led by strong and talented team of executives and advisors providing expert acquisition, market guidance and added value for subsidiaries and investors.
FORWARD LOOKING STATEMENT: This news release contains forward looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. These risks include the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources, and the impact of competitive pricing. In the light of these uncertainties the forward-looking events referred to in this release might not occur.
Investors Relations 800-628-2100 ext. 705
investorsrelations@cardifflexington.com
Source: Cardiff Lexington Corporation
> Dow Jones Newswires
August 23, 2019 10:10 ET (14:10 GMT)
Great news!
You would think someone would take a flyer and buy 50 million to 100 million shares. But apparently not.
It was just an LOI. Nothing if anything will be happening for awhile. Traders will get bored and sell. Then this stock is notorious for dilution so it will be a double whammy of selling and conversions.
Yes, I think this stock is getting ready to launch again soon.
It's just in the LOI stage.
I don't know but if they do $30 million in revenues that's good enough for me.
I might have been overly optimistic with 50/50. Sorry about that
PACV signed the LOI on June 26th
https://www.otcmarkets.com/stock/PACV/news/story?e&id=1384811
They signed the Asset Purchase agreement on August 21st
https://www.otcmarkets.com/stock/PACV/news/story?e&id=1420892
Next will be the 8K
Try google. It's just an LOI
$460,000 market cap for a company trending at almost $4 million in revenues. The stock is undervalued. Maybe we should get Warren Buffet on the phone.
It's just an LOI. There is a 50/50 chance it will ever come to fruition.
And guess what they will be distributing? Probably SnoBar? That is called vertically integrated marketing at its finest
Yes, positive upward corrections are always a good thing
Solid buying today absorbing the profit takers.
This stock is trending at $4 million in yearly revenues and that doesn't include the potential $30 million acquisition
Nice little stock here. My little PACV
Trending towards $4 million in revenues with a market cap of only $460,000. This stock is severely undervalued regardless of whether there is a reverse split or not.
The market cap is only $2.5 million after yesterday's run. Their current subsidiaries are worth more than that. Their Platinum Defender subsidiary is trending at $3 million in sales on its own.
Filings are what is needed to make things more official
I think we will get word soon
On July 23rd an attorney's letter was filed with the OTC so maybe they have something in the works in terms of another merger candidate.
DCAC will go up 500% to 1000% if he gets denied. It should be trading between .0005 and .001 right now based on revenues.
If it gets accepted the stock will have a very low float and it will get squeezed and the stock will go up 500% to 1000% that way.
Either way the stock is going up from here. Its just a waiting game. The market cap is only $460,000 with revenues trending at $4 million. Its dirt cheap at this level.
The uptrend should resume in a couple of months. It had a nice run.
I am expecting a 5 to 10 bagger here based on the revenues and the very low market cap
Only filings will move this stock. That might take awhile
If it becomes a low floater we should see a float squeeze and a price run up. If it stays the way it is the stock should be trading at .0008 to .001. Either way the stock should do well. I am surprised there isn't more interest